XML 77 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1

Significant Agreements (Details)		1 Months Ended		3 Months Ended		12 Months Ended
	Apr. 03, 2018 USD ($) shares	Dec. 31, 2021 USD ($) item	Jan. 31, 2016 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) item	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Feb. 26, 2010 USD ($)
Significant Agreements
Revenue						$ 77,428,000	$ 23,638,000	$ 3,154,000
One-time non-refundable development milestone payment	$ 70,000,000
RareStone Group Ltd.
Significant Agreements
Number of independent sub studies in patients | item								4
Upfront payment		$ 7,000,000
Equity issued in conjunction with license agreement		1,077,586
Aggregate payment upon achievement of development and commercial milestones		62,500,000						$ 62,500,000
Equity recorded at fair value		$ 1,040,000			$ 1,040,000			1,040,000	$ 2,440,000
Realized loss on RareStone equity				$ 1,040,000
Loss on RareStone equity investment					$ 300,000
Upfront consideration								8,040,000
Number of performance obligations | item		2
License agreement commercial manufacturing supply discount							1,286,000
Contract with customer liability revenue recognized							6,754,000
Ipsen | License agreement
Significant Agreements
Amount of commercial milestone capitalized									$ 4,000,000	$ 5,000,000
Milestone expenses						0	0	0
Ipsen | License agreement | Maximum
Significant Agreements
Aggregate payment upon achievement of development and commercial milestones											$ 40,000,000
Ipsen | Sublicense agreement | Minimum
Significant Agreements
Payment based on revenue received, as percentage											10.00%
Ipsen | Sublicense agreement | Maximum
Significant Agreements
Payment based on revenue received, as percentage											20.00%
Camurus | License agreement
Significant Agreements
Milestone expenses						0	1,000,000	0
Non-refundable and non-creditable signing fee			$ 500,000
Royalty payment period			10 years
Camurus | License agreement | Maximum
Significant Agreements
One-time non-refundable development milestone payment			$ 7,750,000
One-time non-refundable non-creditable sales milestone payment			$ 57,000,000
Takeda
Significant Agreements
Equity issued in conjunction with license agreement	4,448,000
Milestone expenses						0	0	0
One-time non-refundable development milestone payment	$ 70,000,000
Shares issued for license agreement (in shares) | shares	223,544
Period after date of first commercial sale (in years)	10 years
License revenue
Significant Agreements
Revenue						$ 0	$ 6,754,000	$ 0

X

- Definition

Represent the amount of aggregate payment upon achievement of development and commercial milestones.

+ References

No definition available.

+ Details

Name:	rytm_AggregatePaymentUponAchievementOfDevelopmentAndCommercialMilestones
Namespace Prefix:	rytm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of commercial milestone capitalized as a finite lived intangible asset from first commercial sale.

+ References

No definition available.

+ Details

Name:	rytm_CommercialMilestoneAmountCapitalized
Namespace Prefix:	rytm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of discount on commercial manufacturing supply in license agreement.

+ References

No definition available.

+ Details

Name:	rytm_LicenseAgreementCommercialManufacturingSupplyDiscount
Namespace Prefix:	rytm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The number of performance obligations in license agreement.

+ References

No definition available.

+ Details

Name:	rytm_LicenseAgreementNumberOfPerformanceObligations
Namespace Prefix:	rytm_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of upfront consideration received on license agreement.

+ References

No definition available.

+ Details

Name:	rytm_LicenseAgreementUpfrontConsideration
Namespace Prefix:	rytm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the amount of milestone expenses.

+ References

No definition available.

+ Details

Name:	rytm_MilestoneFee
Namespace Prefix:	rytm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the amount of non-refundable and non-creditable signing fee.

+ References

No definition available.

+ Details

Name:	rytm_NonRefundableAndNonCreditableSigningFee
Namespace Prefix:	rytm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The number of independent sub studies conducted in patients.

+ References

No definition available.

+ Details

Name:	rytm_NumberOfIndependentSubStudiesInPatients
Namespace Prefix:	rytm_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of one-time non-refundable non-creditable sales milestone payment upon achievement of certain sales levels.

+ References

No definition available.

+ Details

Name:	rytm_OnetimeNonRefundableNonCreditableSalesMilestonePaymentUponAchievementOfCertainSalesLevels
Namespace Prefix:	rytm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Represents the amount of one-time non-refundable development milestone payment upon achievement of certain regulatory successes.

+ References

No definition available.

+ Details

Name:	rytm_OnetimeNonrefundableDevelopmentMilestonePaymentUponAchievementOfCertainRegulatorySuccesses
Namespace Prefix:	rytm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents the percentage payment based on revenue received.

+ References

No definition available.

+ Details

Name:	rytm_PaymentPercentageBasedOnRevenuesReceived
Namespace Prefix:	rytm_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The period after the date of the first commercial sale.

+ References

No definition available.

+ Details

Name:	rytm_PeriodAfterDateOfFirstCommercialSale
Namespace Prefix:	rytm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of realized gain (loss) on investment in Rarestone valuation.

+ References

No definition available.

+ Details

Name:	rytm_RarestoneValuationRealizedGainLoss
Namespace Prefix:	rytm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the period for royalty payment after first commercial sale.

+ References

No definition available.

+ Details

Name:	rytm_RoyaltyPaymentPeriodAfterFirstCommercialSale
Namespace Prefix:	rytm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of new stock issued during the period from license agreement.

+ References

No definition available.

+ Details

Name:	rytm_StockIssuedDuringPeriodSharesNewIssuesLicenseAgreement
Namespace Prefix:	rytm_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Equity impact of the value of new stock issued during the period from license agreement.

+ References

No definition available.

+ Details

Name:	rytm_StockIssuedDuringPeriodValueNewIssuesLicenseAgreement
Namespace Prefix:	rytm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the amount of an upfront payment.

+ References

No definition available.

+ Details

Name:	rytm_UpfrontPayment
Namespace Prefix:	rytm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

+ Details

Name:	us-gaap_GainLossOnContractTermination
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Fair value portion of other assets.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherAssetsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=rytm_RareStoneGroupLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=rytm_IpsenPharmaSasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=rytm_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=rytm_SublicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=rytm_CamurusAbMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=rytm_TakedaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: